Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecaprevir - AbbVie/Enanta Pharmaceuticals

Next Previous
X
Search
Drug Profile

Glecaprevir - AbbVie/Enanta Pharmaceuticals

Alternative Names: ABT-493; Next-generation HCV protease inhibitor - AbbVie/Enanta

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Cyclic ethers; Cyclopentanes; Cyclopropanes; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 15 Oct 2019 AbbVie completes a phase II non-treatment follow-up trial for Hepatitis C in Canada, Australia, United Kingdom, Puerto Rico, New Zealand, USA, Belgium and Germany (NCT02441283) (EudraCT2015-000452-24)
  • 25 Jun 2019 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO)
  • 25 Jun 2019 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in USA, Puerto Rico, New Zealand, Australia, Australia, Canada, France, Germany, Italy, Spain, United Kingdom, South Korea, Taiwan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top